Skip to main content
NASDAQ:FTSV

Forty Seven Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
$95.51
0.00 (0.00 %)
(As of 04/7/2020)
Add
Compare
Today's Range
$95.51
$95.51
50-Day Range
$95.51
$95.51
52-Week Range
$5.53
$95.51
VolumeN/A
Average Volume1.61 million shs
Market Capitalization$4.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.4

Competitors

Forty Seven (NASDAQ:FTSV) Vs. CTLT, ELAN, ALNY, ZLAB, BMRN, and GRFS

Should you be buying FTSV stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Forty Seven, including Catalent (CTLT), Elanco Animal Health (ELAN), Alnylam Pharmaceuticals (ALNY), Zai Lab (ZLAB), BioMarin Pharmaceutical (BMRN), and Grifols (GRFS).

Catalent (NYSE:CTLT) and Forty Seven (NASDAQ:FTSV) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Insider & Institutional Ownership

97.8% of Catalent shares are owned by institutional investors. Comparatively, 71.8% of Forty Seven shares are owned by institutional investors. 1.0% of Catalent shares are owned by insiders. Comparatively, 37.4% of Forty Seven shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Catalent has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Forty Seven has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.

Profitability

This table compares Catalent and Forty Seven's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
Forty SevenN/A-50.38%-44.35%

Earnings & Valuation

This table compares Catalent and Forty Seven's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion5.65$173 million$1.8854.63
Forty Seven$15.68 million293.33$-87,620,000.00($2.34)-40.82

Catalent has higher revenue and earnings than Forty Seven. Forty Seven is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Catalent and Forty Seven, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01702.88
Forty Seven0000N/A

Catalent presently has a consensus price target of $125.1250, suggesting a potential upside of 21.84%. Given Catalent's higher possible upside, analysts clearly believe Catalent is more favorable than Forty Seven.

Summary

Catalent beats Forty Seven on 11 of the 13 factors compared between the two stocks.

Elanco Animal Health (NYSE:ELAN) and Forty Seven (NASDAQ:FTSV) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Insider & Institutional Ownership

86.8% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 71.8% of Forty Seven shares are owned by institutional investors. 0.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 37.4% of Forty Seven shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Elanco Animal Health has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Forty Seven has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.

Profitability

This table compares Elanco Animal Health and Forty Seven's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elanco Animal Health-8.45%3.43%2.04%
Forty SevenN/A-50.38%-44.35%

Earnings & Valuation

This table compares Elanco Animal Health and Forty Seven's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elanco Animal Health$3.07 billion5.36$67.90 million$1.0632.83
Forty Seven$15.68 million293.33$-87,620,000.00($2.34)-40.82

Elanco Animal Health has higher revenue and earnings than Forty Seven. Forty Seven is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Elanco Animal Health and Forty Seven, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elanco Animal Health13902.62
Forty Seven0000N/A

Elanco Animal Health presently has a consensus price target of $32.2273, suggesting a potential downside of 7.39%. Given Elanco Animal Health's higher possible upside, analysts clearly believe Elanco Animal Health is more favorable than Forty Seven.

Summary

Elanco Animal Health beats Forty Seven on 9 of the 13 factors compared between the two stocks.

Forty Seven (NASDAQ:FTSV) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Earnings and Valuation

This table compares Forty Seven and Alnylam Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forty Seven$15.68 million293.33$-87,620,000.00($2.34)-40.82
Alnylam Pharmaceuticals$219.75 million72.59$-886,120,000.00($8.11)-16.73

Forty Seven has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Forty Seven is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Forty Seven and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Forty SevenN/A-50.38%-44.35%
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%

Insider & Institutional Ownership

71.8% of Forty Seven shares are owned by institutional investors. Comparatively, 92.4% of Alnylam Pharmaceuticals shares are owned by institutional investors. 37.4% of Forty Seven shares are owned by company insiders. Comparatively, 3.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Forty Seven has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Forty Seven and Alnylam Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forty Seven0000N/A
Alnylam Pharmaceuticals08802.50

Alnylam Pharmaceuticals has a consensus target price of $168.7333, suggesting a potential upside of 24.34%. Given Alnylam Pharmaceuticals' higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Forty Seven.

Summary

Alnylam Pharmaceuticals beats Forty Seven on 7 of the 13 factors compared between the two stocks.

Forty Seven (NASDAQ:FTSV) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Earnings and Valuation

This table compares Forty Seven and Zai Lab's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forty Seven$15.68 million293.33$-87,620,000.00($2.34)-40.82
Zai Lab$12.98 million1,115.58$-195,070,000.00($3.03)-50.47

Forty Seven has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Forty Seven, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Forty Seven and Zai Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Forty SevenN/A-50.38%-44.35%
Zai LabN/AN/AN/A

Insider & Institutional Ownership

71.8% of Forty Seven shares are owned by institutional investors. Comparatively, 81.3% of Zai Lab shares are owned by institutional investors. 37.4% of Forty Seven shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Forty Seven has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Forty Seven and Zai Lab, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forty Seven0000N/A
Zai Lab00503.00

Zai Lab has a consensus target price of $197.8460, suggesting a potential upside of 29.37%. Given Zai Lab's higher possible upside, analysts plainly believe Zai Lab is more favorable than Forty Seven.

Summary

Zai Lab beats Forty Seven on 7 of the 12 factors compared between the two stocks.

Forty Seven (NASDAQ:FTSV) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Earnings and Valuation

This table compares Forty Seven and BioMarin Pharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forty Seven$15.68 million293.33$-87,620,000.00($2.34)-40.82
BioMarin Pharmaceutical$1.70 billion8.25$-23,850,000.00$0.071,099.00

BioMarin Pharmaceutical has higher revenue and earnings than Forty Seven. Forty Seven is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Forty Seven and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Forty SevenN/A-50.38%-44.35%
BioMarin Pharmaceutical45.74%4.34%2.84%

Insider & Institutional Ownership

71.8% of Forty Seven shares are owned by institutional investors. Comparatively, 97.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 37.4% of Forty Seven shares are owned by company insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Forty Seven has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Forty Seven and BioMarin Pharmaceutical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forty Seven0000N/A
BioMarin Pharmaceutical071002.59

BioMarin Pharmaceutical has a consensus target price of $118.20, suggesting a potential upside of 53.65%. Given BioMarin Pharmaceutical's higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Forty Seven.

Summary

BioMarin Pharmaceutical beats Forty Seven on 11 of the 13 factors compared between the two stocks.

Forty Seven (NASDAQ:FTSV) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Earnings and Valuation

This table compares Forty Seven and Grifols' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forty Seven$15.68 million293.33$-87,620,000.00($2.34)-40.82
Grifols$5.71 billion2.26$700.16 million$1.1716.02

Grifols has higher revenue and earnings than Forty Seven. Forty Seven is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Forty Seven and Grifols' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Forty SevenN/A-50.38%-44.35%
Grifols12.79%10.65%4.79%

Insider & Institutional Ownership

71.8% of Forty Seven shares are owned by institutional investors. Comparatively, 15.2% of Grifols shares are owned by institutional investors. 37.4% of Forty Seven shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Forty Seven has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Forty Seven and Grifols, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forty Seven0000N/A
Grifols03502.63

Summary

Grifols beats Forty Seven on 9 of the 12 factors compared between the two stocks.


Forty Seven Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Catalent logo
CTLT
Catalent
1.7$102.70flat$17.49 billion$3.09 billion65.41Analyst Revision
News Coverage
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.9$34.80flat$16.46 billion$3.07 billion-61.05Analyst Upgrade
Insider Buying
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$135.70flat$15.95 billion$219.75 million-17.33
Zai Lab logo
ZLAB
Zai Lab
1.6$152.93flat$14.48 billion$12.98 million-50.47Earnings Announcement
Analyst Revision
News Coverage
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$76.93flat$14.06 billion$1.70 billion17.60Insider Selling
Grifols logo
GRFS
Grifols
1.3$18.74flat$12.88 billion$5.71 billion16.73News Coverage
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$72.00flat$11.97 billion$2.32 billion59.50Upcoming Earnings
News Coverage
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.57flat$11.54 billion$16.89 billion-2.87Insider Selling
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$29.07flat$10.42 billion$8.60 billion-5.33
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$179.17flat$10.19 billion$2.16 billion56.52Analyst Upgrade
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.5$37.93flat$9.77 billionN/A0.00Earnings Announcement
Analyst Report
Lockup Expiration
Analyst Revision
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.7$197.87flat$8.86 billion$1.45 billion18.72Analyst Report
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$156.62flat$8.06 billion$3.34 million-20.34Analyst Revision
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$53.66flat$8.01 billion$40.56 million-15.74Analyst Report
News Coverage
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$72.83flat$7.58 billion$87.99 million-86.70
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$110.88flat$7.48 billion$103.71 million-25.26Analyst Upgrade
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$132.18flat$7.10 billion$14.98 million-16.10Upcoming Earnings
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96flat$6.86 billion$311.33 million-127.30
Perrigo logo
PRGO
Perrigo
2.2$45.86flat$6.13 billion$4.84 billion-764.21Earnings Announcement
Unusual Options Activity
Analyst Revision
News Coverage
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$76.05flat$6.07 billion$380.83 million-9.73
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$96.45flat$5.63 billion$66.51 million17.80Insider Selling
Allakos logo
ALLK
Allakos
1.7$100.64flat$5.39 billionN/A-36.73Earnings Announcement
Analyst Downgrade
Insider Selling
Analyst Revision
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$38.24flat$5.39 billion$1.12 billion79.67Analyst Report
Galapagos logo
GLPG
Galapagos
1.3$76.18flat$4.99 billion$1.00 billion-11.54Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$34.26flat$4.85 billion$150,000.00-16.16Earnings Announcement
Unusual Options Activity
Analyst Revision
I-Mab logo
IMAB
I-Mab
1.0$64.89flat$4.70 billion$4.31 million-2.25Gap Up
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.85flat$4.55 billionN/A-5.69Earnings Announcement
Analyst Report
Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.6$61.24flat$4.29 billion$85.54 million0.00Analyst Report
Insider Selling
Analyst Revision
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.6$70.86flat$4.14 billion$6.87 million-6.85
LEGN
Legend Biotech
1.3$29.60flat$3.94 billion$64.39 million0.00High Trading Volume
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$25.81flat$3.84 billion$204.89 million-32.26
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$61.46flat$3.73 billion$806.43 million-8.71Analyst Report
Alkermes logo
ALKS
Alkermes
1.2$22.26flat$3.57 billion$1.17 billion-48.39Insider Selling
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$44.26flat$3.56 billionN/A-5.96
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.77flat$3.49 billion$339.08 million-12.66Analyst Report
Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.98flat$3.46 billion$114.62 million-7.65Insider Selling
Analyst Revision
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$69.35flat$3.41 billionN/A-19.76Analyst Upgrade
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$55.22flat$3.40 billion$117.91 million-11.20
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$113.83flat$3.35 billionN/A-56.63Analyst Report
Insider Selling
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$62.00flat$3.32 billion$1.11 billion19.94Analyst Report
Gap Up
Arvinas logo
ARVN
Arvinas
1.7$66.91flat$3.28 billion$42.98 million-26.14
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$37.60flat$3.05 billion$60,000.00-11.68Earnings Announcement
Analyst Upgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$78.35flat$2.84 billion$26.52 million-6.90
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$73.95flat$2.83 billion$644.77 million-10.55Upcoming Earnings
MorphoSys logo
MOR
MorphoSys
0.3$20.91flat$2.75 billion$80.43 million99.58
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.3$62.21flat$2.74 billion$421.03 million21.90Analyst Report
Insider Selling
Insmed logo
INSM
Insmed
1.2$26.23flat$2.71 billion$136.47 million-10.09Analyst Downgrade
Unusual Options Activity
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$37.99flat$2.68 billion$306.98 million-5.43
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$40.91flat$2.59 billionN/A-22.48Earnings Announcement
Insider Selling
Analyst Revision
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.4$9.49flat$2.52 billion$182.24 million-8.25Earnings Announcement
Analyst Revision
News Coverage
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.